Invado Pharmaceuticals Announced the Acceptance of a NeutraSal Antimicrobial Pilot Study Poster at American Radium Society 95th Annual Meeting

Share Article

Invado Pharmaceuticals announced the acceptance of a NeutraSal antimicrobial pilot study poster at American Radium Society 95th Annual Meeting held in Scottsdale, AZ. In the study results, NeutraSal demonstrated antimicrobial properties that may benefit cancer patients.

Invado Pharmaceuticals announced the acceptance of a NeutraSal antimicrobial pilot study poster at American Radium Society 95th Annual Meeting held in Scottsdale, AZ. In the study results, NeutraSal demonstrated antimicrobial properties that may benefit cancer patients.

Studies have shown that patients undergoing radiation therapy of the head and neck are more susceptible to bacteria and fungal infections of the mouth. An in vitro time kill study utilizing NeutraSal was undertaken to assess the antimicrobial properties of NeutraSal when challenged against opportunistic pathogens such as candida and bacteria. The results of the study indicated that NeutraSal has antimicrobial activity against both candida albicans and streptococcus mutans. NeutraSal may be used safely as part of an oral hygiene program that helps decontaminate the mouth in at risk patients including head and neck cancer patients undergoing radiation therapy or chemotherapy.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Edward Kobus
Invado Pharmaceuticals
(866) 963-8881
Email >